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TO THE EDITOR
Adult T-cell leukemia/lymphoma
(ATLL) is a peripheral T-cell neoplasm
caused by human T-cell leukemia virus
type 1 (Ohshima et al., 2008). There are
four clinical subtypes of ATLL: acute,
lymphoma, chronic, and smoldering
(Shimoyama, 1991). Although acute
and lymphoma types are associated
with a highly aggressive clinical course,
chronic and smoldering types usually
have an indolent course. More than half
of ATLL patients present with cutaneous
lesions (Ohshima et al., 2008). In some
cases skin is the only site of lymphoma
involvement and there is no involve-
ment of other organs including periph-
eral blood and lymph nodes. These
cases are considered to be the primary
cutaneous form of ATLL and have been
designated as cutaneous type (Johno
et al., 1992), although they are in-
cluded among the smoldering type
according to the current classification
(Shimoyama, 1991). Prognosis of cuta-
neous-type ATLL, especially those with
cutaneous tumors, is worse than that of
smoldering type without cutaneous in-
volvement (Johno et al., 1992; Setoya-
ma et al., 1999; Yamaguchi et al.,
2005; Bittencourt et al., 2007, 2009).
However, cutaneous-type patients who
present only with patches and/or
plaques, clinically and histologically
indistinguishable from lesions of myco-
sis fungoides (MF), may develop cuta-
neous tumors or extracutaneous disease
only after a protracted period (Johno
et al., 1992; Setoyama et al., 1999;
Bittencourt et al., 2007, 2009). Differ-
ential diagnosis of these cases from MF
is often difficult and can be made only
by demonstration of the clonal integra-
tion of human T-cell leukemia virus type
1 proviral DNA in the cutaneous lesions.
Important roles of the human T-cell
leukemia virus type 1 Tax protein
(Peloponese et al., 2007) and basic
zipper factor mRNA (Satou and Matsuo-
ka, 2007) in the oncogenesis of ATLL
have been established. The long latency
period before onset of ATLL indicates that
in addition to viral components, cytoge-
netic changes acquired over time in the
host genome of human T-cell leukemia
virus type 1-infected T cells would be
required for the development of full-
blown ATLL (Okamoto et al., 1989).
Although genetic and epigenetic aberra-
tions that may be associated with the
oncogenesis of particular types of ATLL
or disease progression have been re-
ported (Kamada et al., 1992; Nosaka
et al., 2000; Itoyama et al., 2001;
Tsukasaki et al., 2001; Yasunaga et al.,
2004; Sasaki et al., 2005; Yamada and
Kamihira, 2005; Oshiro et al., 2006), no
cytogenetic hallmark of ATLL has been
identified. Furthermore, these abnormal-
ities are found mainly in the aggressive
(acute and lymphoma) types (Kamada
et al., 1992; Itoyama et al., 2001;
Tsukasaki et al., 2001; Sasaki et al.,
2005; Yamada and Kamihira, 2005;
Oshiro et al., 2006), and no specific
cytogenetic aberration has been identi-
fied in the indolent types including the
cutaneous type.
Deletion or disrupting translocation
of NAV3 (neuron navigator 3) gene is a
recently described recurrent cytoge-
netic abnormality in MF and related
Se´zary syndrome (Karenko et al., 2005).
Although some of the subsequent stu-
dies by other groups failed to confirm
this finding (Carbone et al., 2008; Marty
et al., 2008), the discrepancy might be
explained by the different case series
analyzed or by the different detection
methods used in these studies (Karenko
et al., 2005; Carbone et al., 2008;
Marty et al., 2008; Vermeer et al.,
2008). Allelic NAV3 deletion has also
been shown to have a role in the
oncogenesis of subcutaneous pannicu-
litis-like T-cell lymphoma (Hahtola
et al., 2008a) and other cancers (Hah-
tola et al., 2008b; Bleeker et al., 2009;
Soon et al., 2009). Importantly, NAV3
gene deletion may be a relatively early
event in the development of MF,
because it was found in 50% of the
early MF cases (Karenko et al., 2005).
The close clinical and histological
resemblance between cutaneous-type
ATLL with MF-like manifestations and
early MF led us to hypothesize that
NAV3 deletion has a role also in the
oncogenesis of cutaneous-type ATLL.
To determine whether aberrations of
NAV3 gene are present in ATLL, we
analyzed the status of NAV3 gene in
cutaneous lesions of ATLL, in particular
those of cutaneous type, by multicolor
fluorescence in situ hybridization on
interphase nuclei isolated from paraffin-
embedded skin biopsy samples (Karen-
ko et al., 2005; Hahtola et al., 2008b).
Locus-specific fluorescence in situ hy-
bridization using bacterial artificial
chromosome probes covering NAV3
gene and a chromosome 12 centro-
mere-specific probe was performed asAbbreviations: ATLL, adult T-cell leukemia/lymphoma; MF, mycosis fungoides
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described (Karenko et al., 2005), and
the signal copy number was counted
from at least 100 randomly chosen
nonoverlapping nuclei. Nuclei with
higher number of fluorescence signals
from the centromere probe than that
from the NAV3 probe were considered
NAV3 deletion. When more than 4% of
the cell nuclei showed NAV3 deletion,
the sample was considered abnormal
according to the instructions of the
manufacturer of the NAV3 fluorescence
in situ hybridization-kit (Dermagene
Oy, Tampere, Finland).
As summarized in Table 1, among
28 skin biopsy samples from 23 cases of
ATLL, six samples showed chromosome
12 trisomy or tetrasomy. Allelic dele-
tion of NAV3 gene was found only in
two samples that also had chromosome
12 polysomy (Table 1). Both of these
Table 1. Aberrations of chromosome 12 and NAV3 gene in cutaneous lesions of patients with ATLL
Percentage of abnormal cells
Copy number in the dominant
abnormal cells
Case Clinical type1 Sample Previous therapy
Chromosome 12
polysomy NAV3 deletion
Chromosome 12
centromere NAV3
1 Acute Papule None 2% 4%
2 Acute Papule None 2% 0%
3 Acute Papule None 2% 0%
Tumor None 2% 0%
4 Acute Tumor None 2% 1%
5 Lymphoma Tumor None 3% 2%
Tumor2 THP-COP, oral
ETP+PDN
75% 62% 4 3
6 Lymphoma Tumor2 VCAP-AMP-VECP 63% 57% 3 2
7 Lymphoma Tumor None 77% 3% 4 4
8 Lymphoma Tumor None 58% 2% 4 4
9 Chronic Tumor None 2% 0%
10 Chronic Tumor None 44% 0% 3 3
Patch/plaque oral ETP+PDN, PUVA 1% 2%
11 Smoldering Patch/plaque None 1% 2%
12 Smoldering Tumor PUVA 0% 1%
Tumor PUVA 4% 0%
13 Cutaneous Tumor None 1% 1%
14 Cutaneous Tumor None 2% 1%
15 Cutaneous Tumor None 1% 1%
16 Cutaneous Tumor None 1% 1%
17 Cutaneous Tumor None 2% 1%
18 Cutaneous Tumor None 78% 4% 4 4
19 Cutaneous Papule IFN-g, PUVA, NB-UVB 1% 1%
20 Cutaneous Patch/plaque None 1% 0%
21 Cutaneous Patch/plaque None 3% 1%
22 Cutaneous Patch/plaque None 2% 0%
23 Cutaneous Patch/plaque None 2% 1%
Tumor PUVA, NB-UVB,
radiotherapy, IFN-g, oral
ETP+PDN
4% 1%
AMP, doxorubicin, ranimustine, and prednisone; ETP, etoposide; IFN-g, interferon-g; NB-UVB, narrowband ultraviolet B phototherapy; PDN, prednisone;
PUVA, psolaren plus ultraviolet A phototherapy; THP-COP, cyclophosphamide, pirarubicin, vincristine, and prednisone; VCAP, vincristine, cyclopho-
sphamide, doxorubicin, and prednisone; VECP, vindesine, etoposide, carboplatin, and prednisone.
1Clinical types of ATLL were determined according to the Shimoyama criteria (Shimoyama, 1991). Cutaneous type was defined by the presence of
histologically confirmed cutaneous lymphoma with clonal integration of HTLV-1 proviral DNA, normal lymphocyte level (o4 109/l), o5% abnormal
lymphocytes in peripheral blood, no hypercalcemia, serum lactate dehydrogenase level up to 1.5 times the normal upper limit, and no involvement of
extracutaneous organs. The patients with smoldering-type ATLL had X5% abnormal lymphocytes in peripheral blood.
2These samples were taken from recurrent or refractory cutaneous lesions of the patients after combination chemotherapy.
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two samples were taken from cuta-
neous tumors of lymphoma-type ATLL.
Both samples were from recurrent/
refractory lesions after intensive combi-
nation chemotherapy. In one case the
pretreatment sample did not show
chromosome 12 polysomy or NAV3
deletion (case 5). It can be speculated
that the NAV3 deletion in these sam-
ples resulted from larger chromosome
12 aberrations secondary to chemother-
apy, but because two other patients
who received low-dose oral che-
motherapy (cases 10 and 23) did not
show NAV3 deletion, another possibi-
lity is that allelic loss of NAV3 was
associated with the recurrence proper-
ties of the tumor.
Notably, none of the six cases of
ATLL that resembled clinically and
histologically tumor-stage (cases 17,
18, and 23) or early patch/plaque-stage
(cases 20–23) of MF showed NAV3
deletion. Therefore, NAV3 gene would
not be frequently deleted in cutaneous-
type ATLL including those with MF-like
manifestations as compared with MF.
Our results suggest that despite the
strong resemblance between cuta-
neous-type ATLL and MF, distinct cyto-
genetic aberrations contribute to their
development.
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